MR 409 |
Katalog-Nr.GC72181
One-Click Copy Product Info
|
MR 409 ist ein ausgewählter Agonist des Wachstumshormons (GHRH).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1445155-39-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo[1].
MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs)[2].
MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2[2].
MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner[3].
MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect[3].
MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect[3].
MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion[4].
MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice[3].
MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice[3].
References:
[1]. Rosemeire M Kanashiro-Takeuchi, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39.
[2]. Mohammad A Uddin, et al. GHRH antagonists support lung endothelial barrier function. Tissue Barriers. 2019;7(4):1669989.
[3]. Lucia Recinella, et al. Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Sci Rep. 2021 Jan 28;11(1):2530.
[4]. Yueyang Liu, et al. Agonistic analog of growth hormone-releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2109600118.
| Cas No. | 1445155-39-4 | SDF | |
| Formula | C153H252N44O43 | M.Wt | 3395.91 |
| Löslichkeit | Storage | Sealed storage, away from moisture and light, under nitrogen | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 294.5 μL | 1.4724 mL | 2.9447 mL |
| 5 mM | 58.9 μL | 294.5 μL | 588.9 μL |
| 10 mM | 29.4 μL | 147.2 μL | 294.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)